Medtronic FY2027 Q1 Earnings Beat Expectations, Full-Year Guidance Raised on Both Fronts
nashnova research
Medtronic posted Q1 revenue of $9.76 billion, up ~14% year-over-year and $220 million above consensus, then raised full-year organic growth and EPS guidance — management credited broad-based strength rather than any single driver.
How big was the beat?
Q1 total revenue hit $9.76 billion, topping consensus by roughly $220 million. Adjusted EPS came in at $1.45, $0.06 above estimates, up ~15% year-over-year.
Adjusted gross margin reached 65.2% and operating margin 23.7% — gross margin alone beat the Street's 64.8% call by nearly half a point.
This means → it was not just a top-line beat. Profitability improved alongside volume, which sends a stronger fundamental signal than revenue growth alone.
Which business line drove the most?
Cardiovascular stood out: quarterly revenue of $3.93 billion, up ~20% year-over-year, clearing analysts' $3.78 billion estimate. In plain terms = demand for structural-heart and cardiac-rhythm devices — implants that repair heart structure or regulate heartbeat — is still expanding fast.
Neuroscience posted $2.68 billion (+~10%, slightly above consensus); Medical Surgical posted $2.28 billion (+~10%, also above consensus).
Diabetes revenue was $843 million, ahead of the $822.9 million consensus. This reflects a quarter with no laggards — management's "broad-based" claim checks out across all four segments.
How much did full-year guidance move?
Organic revenue growth guidance lifted from 6.75%–7.25% to 7.25%–7.75%, plus ~1% tailwind from currency-neutral effects.
Non-GAAP EPS guidance midpoint nudged from $5.95 to $5.97, slightly above prior Street consensus.
This means → the raise is deliberate, not aggressive. Management is using the Q1 beat to lift the floor for the full year while keeping a buffer for later quarters.
What do the two strategic deals signal?
Medtronic announced a $700 million deal for exclusive distribution rights to Cornerstone Robotics' Sentire surgical-robot system outside the U.S.
It also committed up to $80 million to Israel-based Pi-Cardia for global exclusive distribution of the ShortCut device.
In plain terms = investing externally while every internal line is growing is a "buy from strength" move — the stronger the earnings backdrop, the easier the market accepts the synergy logic behind these deals.
What to watch next?
The key variable: whether Cardiovascular can sustain ~20% growth. It is Medtronic's fastest engine and the linchpin for any further valuation re-rating.
Guidance was raised conservatively; another beat in subsequent quarters could trigger further upward revisions.
CEO Geoff Martha: "What gives us confidence is not just the strength of the quarter, but the breadth of performance across our businesses and the increasing contribution from new growth platforms."
市场有风险，内容仅供研究参考，不构成投资建议。